Boehringer Ingelheim Collaborates with Healx to Identify New Treatments for Rare Neurological Diseases

 Boehringer Ingelheim Collaborates with Healx to Identify New Treatments for Rare Neurological Diseases

Boehringer Ingelheim Collaborates with Healx to Identify New Treatments for Rare Neurological Diseases

Shots:

  • BI and Healx team up to discover new indications targeting rare neurological diseases by harnessing Healx’s AI-based drug discovery platform, Healnet to advance BI’s pipeline
  • The collaboration combines BI’s expertise for drug development, especially in rare neurological conditions with Healx’s AI-powered drug discovery platform. Healx will utilize its data analysis and technological capabilities to help BI in prioritizing selected indications for further research
  • Additionally, Healx has its experience in fragile X syndrome as well as Pitt-Hopkins syndrome and has identified 8 drug candidates for fragile X syndrome leveraging Healnet, out of which 1 is progressing towards P-IIa study

Click here to­ read full press release/ article | Ref: Healx | Image: Crunchbase

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post